EYLEAź (aflibercept) injection demonstrates significantly greater gains in visual acuity
Regeneron announced the NIH sponsored Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema, EYLEAź (aflibercept) Injection demonstrated a significantly greater improvement in mean change in BCVA from baseline at 52 weeks. October 17, 2014